Lilly Oncology has hired Maura Dickler, MD, to serve as vice president of late phase development, beginning May 7, 2018. She will report to Levi Garraway, MD, PhD, senior vice president of global development and medical affairs of Lilly Oncology.
Maura Dickler, MD
Maura Dickler, MD
Lilly Oncology has hired Maura Dickler, MD, to serve as vice president of late phase development, beginning May 7, 2018. She will report to Levi Garraway, MD, PhD, senior vice president of global development and medical affairs of Lilly Oncology.
Known for her prestigious breast cancer research, Dickler’s accomplishments have led her to countless publications and honors. She has been named one ofNew York Magazine’sBest Doctors in Medical Oncology in 2015, 2016, and 2017. She has also been named one of Castle Connolly America’s Top Doctors, and Castle Connolly Exceptional Women in Medicine in 2017.
Since graduating from The University of Chicago’s Pritzker School of Medicine with a fellowship at Memorial Sloan Kettering Cancer Center (MSKCC), Dickler has led numerous clinical trials with a focus on development of therapeutic strategies for treatment of patients with hormone-receptorpositive (HR+) breast cancer.
Some of her trials investigated therapeutic agents targeting growth factor receptor signaling pathways. These pathways include epidermal growth factor receptor (EGFR), human epidermal growth factor receptor (VEGFR), phosphoinositide 3-kinase (PI3K), and the estrogen receptor pathway. Her studies have also looked at cyclin-dependent kinase 4 & 6 (CDK4&6) inhibitors that target the cell cycle.
Dickler currently serves as section head of the Endocrine Therapy Clinical Research Program at MSKCC. She is also an associate member of the Breast Medicine Service in the Department of Medicine at MSKCC and associate professor of medicine at Weill Cornell Medical College, New York.
“Dr Dickler is an internationally recognized oncology leader with drug development expertise spanning a wide range of therapeutic modalities. Moreover, she is an exceptionally gifted clinician for whom patients are at the center of everything she does,” said Garraway in a statement.
UGT1A1 Status Underutilized in Predicting Sacituzumab Toxicity in MBC
April 8th 2024During a Case-Based Roundtable® event, Mark Pegram, MD, discussed the value of testing for UGT1A1 status in patients receiving sacituzumab govitecan for hormone receptor–positive breast cancer in the second article of a 2-part series.
Read More
Survival and Safety Outcomes Factor into Use of Sacituzumab Govitecan in HR+ Breast Cancer
March 29th 2024During a Case-Based Roundtable® event, Mark Pegram, MD, discussed the TROPiCS-02 trial of sacituzumab govitecan in hormone receptor–positive breast cancer in the first article of a 2-part series.
Read More
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
Experts Warn of Radiation Overtreatment in Older Women With Early-Stage Breast Cancer
March 20th 2024Studies have found that omitting radiation therapy after breast-conserving surgery and/or omitting axillary surgery in women age 70 years or older does not affect their survival when taking endocrine therapy.
Read More
Analyzing ADC Treatment Sequencing in Advanced Breast Cancer
March 15th 2024In the first article of a 2-part series, Virginia G. Kaklamani, MD, discussed her approach to biomarker testing and treatment sequencing for patients with hormone receptor–positive, HER2-negative metastatic breast cancer.
Read More